Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Solid Tumor × ulocuplumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Waldenstrom Macroglobulinemia 1 Solid Tumor 1 Leukemia 1

Interventions

Paclitaxel 3 pembrolizumab 2 atezolizumab 2 Nivolumab 2 Docetaxel 2 ulocuplumab 1 tislelizumab 1 tazemetostat 1 tazarotene 1 seviteronel 1 rucaparib 1 romiplostim 1 phosphorylethanolamine 1 pertuzumab 1 neratinib 1 magrolimab 1 fluzoparib 1 fludarabine 1 epacadostat 1 durvalumab 1 camrelizumab 1 Trastuzumab 1 Sunitinib 1 Poly(ADP-ribose) Polymerase Inhibitors 1 LY2510924 1 EC145 1 Cyclophosphamide 1 CH5183284 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02472977 2018-11-01

CXCessoR4

Bristol-Myers Squibb

Phase 1/2 Terminated

61 enrolled 11 charts

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡